Type V Glycogen Storage (McArdle) Disease
OMIM Link for McArdle Disease
Return to The Medical Biochemistry Page
Introduction to McArdle Disease
Glycogen storage disease type V (GSDV) is also known as McArdle disease. This disease was originally described by B. McArdle in 1951, hence the association of his name with the disease. The disease was seen in a 30-year-old patient who was suffering from muscle weakness, pain and stiffness following slight exercise. It was observed that blood lactate fell in this patient during exercise instead of the normal rise that would be seen. This indicated the patient had a defect in the ability to convert muscle glycogen to glucose and ultimately lactate. The identification that the deficiency causing these symptoms was the result of a muscle phosphorylase defect was not made until 1959. Glycogen phosphorylase (most commonly just called phosphorylase) exists in multiple tissue-specific isoforms. The muscle, brain and liver forms are encoded by separate genes. The muscle form is the only isozyme found expressed in mature muscle. The gene for muscle phosphorylase is located on chromosome 11q13-qter. The muscle isoform represents about 50% of total phosphorylase in cardiac muscle, 30% of the brain phosphorylase 30% and is completely absent from the liver. At least 14 different mutations have been identified as causing GSDV.
Clinical Features of McArdle Disease
The clinical presentation of GSDV is usually seen in young adulthood and is characterized by exercise intolerance and muscle cramps following slight exercise. Attacks of myoglobinuria frequently accompany the muscle symptoms of GSDV. About half of GSDV patients will exhibit burgundy colored urine after exercise. Diagnosis of muscle glycogenoses such as GSDV can be made by the observation of a lack of increased blood lactate upon ischemic exercise testing. In addition, there will be an associated large increase in blood ammonia levels. In order to distinguish GSDV from other muscle defects along the pathway from glycogen to glucose to lactate, an enzymatic evaluation of muscle phosphorylase must be done. Also, molecular analysis for known mutations in the muscle phosphorylase gene can be accomplished using DNA extracted from leukocytes.
return to Inborn Errors page
return to Glycogen Metabolism page
Return to The Medical Biochemistry Page
Michael W. King, Ph.D / IU School of Medicine / miking at iupui.edu